210.40p
+2.24%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oxford Nanopore Technologies
Its shares trade on LSE under the ticker ONT.L. It has been listed since 30 September 2021. In the fiscal year to 31 December 2025, it reported revenue of £223.9m and a net loss of £145.2m. At that date it held total assets of £622.5m and shareholders' equity of £463.3m.
Oxford Nanopore Technologies Plc develops proprietary technology platform for the electronic analysis of single molecules. The firm has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. Its segments include Life Science Research Tools (LSRT) and COVID-19 Testing. The LSRT segment offers products and services for research use. The COVID-19 Testing segment provides products for SAR Cov 2 testing. Its sequencing technology offers real-time analysis in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. The firm's products include MinION, GridION, PromethION 2 Solo, PromethION 24 and 48 devices, Flongle and VolTRAX, among others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five Flongle or MinION Flow Cells. PromethION 2 devices are for high-yield sequencing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 30 Sept 2021
- Employees
- 1,009
- Website
- nanoporetech.com ↗
Leadership
Pay as last reported
- Mr. Duncan Tatton-BrownNon-Executive Chairman of the Board£276,640
- Dr. Gurdial SangheraChief Executive Officer, Co-Founder, Executive Director, since 2005£1.8m
- Mr. Nick KeherChief Financial Officer, Executive Director, since 2024£738,157
- Mr. Timothy CowperChief Operating Officer, since 2019£488,979
- Mr. Jordan HermanSenior Vice President, General Counsel
- Mr. Rich ComptonSenior Vice President - Sales and Commercial Operations
- Ms. Sarah LapworthSenior Vice President - Global Human Resources, since 2023
- Ms. Zoe McdougallSenior Vice President - Strategic Communications and Corporate Affairs
- Mr. John SchoellermanSenior Vice President - Corporate and Business Development
- Ms. Rosemary DokosChief Product and Marketing Officer, since 2024
- Dr. Lakmal JayasingheChief Scientific Officer
- Mr. Oliver HartwellVice President - Strategic Planning
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 60
- Environment
- 82
- Social
- 66
- Governance
- 33
- Direct emissions (scope 1)
- 361 t
- Energy emissions (scope 2)
- 1,089 t
- Value chain emissions (scope 3)
- 51,814 t
- Women in the workforce
- 43%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Oxford Nanopore's MinION device enables real-time DNA and RNA sequencing for research applications.
- PromethION 2 devices support high-yield sequencing for large-scale genomic analysis.
- The company's sequencing technology analyzes native DNA or RNA with ultra-long read lengths.
Weaknesses
- The LSRT segment focuses on research use only, limiting commercial applications.
- COVID-19 Testing segment is dependent on pandemic-related demand fluctuations.
- GridION benchtop device runs only up to five Flongle or MinION Flow Cells.
Opportunities
- Expanding Life Science Research Tools segment into new geographic markets.
- Increasing adoption of PromethION 2 Solo for population-scale sequencing projects.
- Growing demand for real-time DNA sequencing in global health initiatives.
Threats
- Competition from established sequencing technology providers in Health Care sector.
- Regulatory changes affecting COVID-19 testing product approvals.
- Economic downturns reducing funding for life science research tools.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.